182 related articles for article (PubMed ID: 31708388)
1. Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent.
Rice SR; Vyfhuis MAL; Scilla KA; Burrows WM; Bhooshan N; Suntharalingam M; Edelman MJ; Feliciano J; Badiyan SN; Simone CB; Bentzen SM; Feigenberg SJ; Mohindra P
Clin Lung Cancer; 2020 May; 21(3):e130-e141. PubMed ID: 31708388
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
Vyfhuis MAL; Bhooshan N; Molitoris J; Bentzen SM; Feliciano J; Edelman M; Burrows WM; Nichols EM; Suntharalingam M; Donahue J; Nagib M; Carr SR; Friedberg J; Badiyan S; Simone CB; Feigenberg SJ; Mohindra P
Lung Cancer; 2017 Dec; 114():44-49. PubMed ID: 29173764
[TBL] [Abstract][Full Text] [Related]
3. Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.
Vyfhuis MAL; Burrows WM; Bhooshan N; Suntharalingam M; Donahue JM; Feliciano J; Badiyan S; Nichols EM; Edelman MJ; Carr SR; Friedberg J; Henry G; Stewart S; Sachdeva A; Pickering EM; Simone CB; Feigenberg SJ; Mohindra P
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):445-452. PubMed ID: 29559292
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Payer Status on Survival of Patients with Stage I/II Non-small Cell Lung Cancer: NCDB 1998-2011.
Shi R; Diaz R; Shi Z; Duvall E; Mills G
Anticancer Res; 2016 Jan; 36(1):319-26. PubMed ID: 26722060
[TBL] [Abstract][Full Text] [Related]
5. Effect of insurance type on perioperative outcomes after robotic-assisted pulmonary lobectomy for lung cancer.
Deol PS; Sipko J; Kumar A; Tsalatsanis A; Moodie CC; Garrett JR; Fontaine JP; Toloza EM
Surgery; 2019 Aug; 166(2):211-217. PubMed ID: 31202473
[TBL] [Abstract][Full Text] [Related]
6. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
7. Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center.
Yorio JT; Yan J; Xie Y; Gerber DE
Clin Lung Cancer; 2012 Nov; 13(6):448-57. PubMed ID: 22512997
[TBL] [Abstract][Full Text] [Related]
8. Disparities in Systemic Treatment Use in Advanced-stage Non-Small Cell Lung Cancer by Source of Health Insurance.
Maguire FB; Morris CR; Parikh-Patel A; Cress RD; Keegan THM; Li CS; Lin PS; Kizer KW
Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1059-1066. PubMed ID: 30842132
[TBL] [Abstract][Full Text] [Related]
9. An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes.
Slatore CG; Au DH; Gould MK;
Am J Respir Crit Care Med; 2010 Nov; 182(9):1195-205. PubMed ID: 21041563
[TBL] [Abstract][Full Text] [Related]
10. Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer.
Moore S; Leung B; Wu J; Ho C
Am J Clin Oncol; 2019 Mar; 42(3):292-297. PubMed ID: 30608237
[TBL] [Abstract][Full Text] [Related]
11. Effect of insurance status on the surgical treatment of early-stage non-small cell lung cancer.
Groth SS; Al-Refaie WB; Zhong W; Vickers SM; Maddaus MA; D'Cunha J; Habermann EB
Ann Thorac Surg; 2013 Apr; 95(4):1221-6. PubMed ID: 23415239
[TBL] [Abstract][Full Text] [Related]
12. Validation of Independent Prognostic Value of Asphericity of
Rogasch JMM; Furth C; Chibolela C; Hofheinz F; Ochsenreither S; Rückert JC; Neudecker J; Böhmer D; von Laffert M; Amthauer H; Frost N
Clin Lung Cancer; 2020 May; 21(3):264-272.e6. PubMed ID: 31839531
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States.
Cushman TR; Jones B; Akhavan D; Rusthoven CG; Verma V; Salgia R; Sedrak M; Massarelli E; Welsh JW; Amini A
Clin Lung Cancer; 2021 Jan; 22(1):e84-e97. PubMed ID: 33039348
[TBL] [Abstract][Full Text] [Related]
14. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
[TBL] [Abstract][Full Text] [Related]
15. Association Between Primary Payer Status and Survival in Patients With Stage III Colon Cancer: An National Cancer Database Analysis.
Ahmed A; Tahseen A; England E; Wolfe K; Simhachalam M; Homan T; Sitenga J; Walters RW; Silberstein PT
Clin Colorectal Cancer; 2019 Mar; 18(1):e1-e7. PubMed ID: 30297265
[TBL] [Abstract][Full Text] [Related]
16. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
Perry AM; Brunner AM; Zou T; McGregor KL; Amrein PC; Hobbs GS; Ballen KK; Neuberg DS; Fathi AT
Cancer; 2017 Jul; 123(13):2561-2569. PubMed ID: 28464280
[TBL] [Abstract][Full Text] [Related]
17. Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.
Raghunathan R; Cease K; Troeschel S; Zhao L; Gross M; Chen G; Chopra V; Ramnath N
Am J Clin Oncol; 2018 May; 41(5):513-518. PubMed ID: 27322696
[TBL] [Abstract][Full Text] [Related]
18. Influence of insurance status and income in anaplastic astrocytoma: an analysis of 4325 patients.
Shin JY; Yoon JK; Diaz AZ
J Neurooncol; 2017 Mar; 132(1):89-98. PubMed ID: 27864706
[TBL] [Abstract][Full Text] [Related]
19. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
Hansen RN; Zhang Y; Seal B; Ryan K; Yong C; Darilay A; Ramsey SD
BMC Cancer; 2020 Apr; 20(1):276. PubMed ID: 32248816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
